The results challenge the rapid growth of Impella support during high-risk PCI. Investigators say a reckoning is needed. Compared with no added support, use of the Impella percutaneous left ventricular assist device (Abiomed) in patients undergoing high-risk nonemergent PCI is associated with more periprocedural MI ...
MassDevice: Johnson & Johnson MedTech shares findings for Impella CP in left ventricle support Johnson & Johnson MedTech shares findings for Impella CP in left ventricle support PHILADELPHIA -- The Impella mechanical support device, frequently used in patients in cardiogenic shock who are undergoing percutaneous coronary interventions, was more expensive than intra-aortic ... Business Wire: Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77% BOSTON--(BUSINESS WIRE)--Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of ... Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77% PHILADELPHIA — Interventional cardiology has taken quite a shine to Impella ventricular assist pumps (Abiomed) for cardiogenic shock (CS) and to support high-risk procedures, but two new observational ...
